Evaxion launches AI-powered automated vaccine design module

COPENHAGEN - Biotech firm Evaxion A/S (NASDAQ:EVAX), a $36 million market cap company whose stock has surged nearly 29% in the past week, announced on Wednesday the launch of a new automated vaccine design module for its AI-Immunology™ platform, which the company says will significantly reduce vaccine development time from months to days. According to InvestingPro data, the company has shown impressive revenue growth of over 1000% in the last twelve months.

The new module automates the previously manual process of vaccine design by optimizing the sequence and conformation of vaccine targets, according to a press release from the clinical-stage TechBio company.

Evaxion’s platform can now perform the complete process of target discovery and vaccine design automatically, potentially improving vaccine quality while reducing development costs, the company stated.

"The new modules significantly enhance our value proposition towards potential partners and increase our in-house capabilities," said Birgitte Rønø, CSO and interim CEO of Evaxion.

The technology can be applied to both new vaccine development and optimization of existing approved vaccines, according to the company.

Evaxion plans to present validation data for the new module at the World Vaccine Congress Europe in Amsterdam on October 15, where Thomas Trolle, Director of Bioinformatics & AI/ML at Evaxion, will deliver a presentation titled "Antigen optimization for infectious disease vaccines using AI-Immunology™."

The company claims the platform addresses common challenges in traditional manual design methods, particularly ensuring proper expression and correct conformations of vaccine targets.

Evaxion’s AI-Immunology™ platform is designed to develop immunotherapies for cancer, bacterial diseases, and viral infections. The company currently has a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline.

In other recent news, Evaxion Biotech has reported several significant developments that may interest investors. The company announced its Q2 2025 earnings, where it highlighted strategic advancements and a robust cash position, despite a noted decrease in stock price. A major highlight is Merck & Co.’s decision to exercise its option to license Evaxion’s preclinical vaccine candidate, EVX-B3, for an upfront payment of $7.5 million. This agreement also positions Evaxion to potentially receive up to $592 million in future development, regulatory, and sales milestone payments, alongside royalties on net sales.

Additionally, H.C. Wainwright has raised its price target for Evaxion Biotech to $16 from $14, maintaining a Buy rating, following Merck’s licensing decision. The pharmaceutical giant has also extended its review period for another Evaxion vaccine candidate, EVX-B2, until the first half of 2026. These recent developments underscore Evaxion’s ongoing collaboration with Merck and its strategic progress in vaccine development.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.